Feng Huang Wang Cai Jing·2025-07-03 11:05Market Overview - A-shares experienced a volatile rise today, with the ChiNext Index increasing nearly 2% and the Shanghai Composite Index reaching a new high for the year. However, this rebound was primarily in the indices and did not translate into gains for individual stocks. The trading volume continued to shrink, totaling 1.33 trillion yuan, down from 1.41 trillion yuan the previous day [1] Sector Performance - Technology stocks generally rebounded, with innovative drug concept stocks showing repeated activity. Solid-state battery concept stocks also saw a recovery from their lows. Apple-related stocks surged, with Industrial Fulian and Pengding Holdings hitting the daily limit, while Lens Technology and Dongshan Precision also experienced significant gains. Notably, Apple's foldable iPhone has entered the prototype development phase, with expectations for a market launch in the second half of 2026 [1] Earnings Forecasts - Multiple stocks with performance forecasts showed active trading, with Meinuohua and Guomai Technology hitting the daily limit. Other stocks like Guangxin Technology, Zongshen Power, Taotao Vehicle, and Xinhengcheng also saw significant gains. Meinuohua has achieved a two-day consecutive limit increase, with its stock price doubling since the low in early April [2] Mid-Year Earnings Season - As July progresses, the traditional mid-year earnings season is about to unfold. Over 30 stocks have released relevant data, with strong performance noted in the biopharmaceutical sector. The best-performing company based on earnings forecasts is Hanyu Pharmaceutical, with an expected profit increase of up to 16 times, primarily due to breakthroughs in the sales of its weight-loss drug, liraglutide, overseas [5] Earnings Forecast Data - Hanyu Pharmaceutical: Expected net profit of approximately 142 million to 162 million yuan, a growth of 1470.82% to 1663.89% [6] - Guoda Special Materials: Expected net profit of approximately 200 million yuan, a growth of 367.51% [6] - Saint Bio: Expected net profit of approximately 77.03 million to 94.14 million yuan, a growth of 253.54% to 332.10% [6] - Other notable forecasts include Meinuohua, Guomai Technology, and Zongshen Power, all showing significant expected growth [6][7] Investment Strategies - Analysts suggest that the upcoming mid-year earnings reports will lead to a focus on structural opportunities in the market. Key investment directions include sectors with strong mid-year earnings, high safety margins, and policy-boosted consumer sectors, as well as core assets in innovative pharmaceuticals [8] Sector Insights - High-growth sectors identified include TMT (technology, media, telecommunications) and industrial products, with specific focus on cinema, gaming, e-commerce, and renewable energy equipment. These sectors are expected to show resilience and growth potential in the coming months [9][12]